[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634124":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":55,"collaborators":25,"id":57,"slug":25,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":25,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-4915","EXPERIMENTAL","Participants will be administered a single dose of ALN-4195.",[13],"Drug: ALN-4915",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ALN-4915 will be administered subcutaneously (SC)",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo will be administered SC",[15],[30],{"name":31,"affiliation":5,"role":32},"Medical Director","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":35,"role":36,"phone":40,"phoneExt":25,"email":38},"1-877-256-9526",[42],{"facility":43,"status":44,"city":45,"state":25,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":25},"Clinical Trial Site","RECRUITING","London","NW10 7EW","United Kingdom","UK",{"type":50,"coordinates":51},"Point",[52,53],-0.12574,51.50853,{"lat":53,"lon":52},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100634124",false,"NCT07535606","A Study to Evaluate ALN-4915 in Adult Healthy Volunteers","A Phase 1, Randomized, Double-Masked, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-4915 in Adult Healthy Volunteers","Inclusion Criteria:\n\n* Is willing and able to complete all study assessments\n\nExclusion Criteria:\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>upper limit of normal (ULN)\n* Has total bilirubin \\>ULN\n* Has no history of invasive infection by an encapsulated organism\n* Has no known complement or immunologic deficiency",true,"ALL","18 Years","65 Years",{"count":68,"type":69},44,"ESTIMATED","INTERVENTIONAL",[72],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.",[75],"Healthy Volunteers",[77,78],"siRNA","RNAi","2026-06-10",{"date":81,"type":82},"2026-06-12","ACTUAL",{"date":84,"type":82},"2026-03-02",{"date":86,"type":69},"2027-07-31",{"name":5,"class":6},1]